Literature DB >> 20233728

Cis-acting genetic variation at an E2F1/YY1 response site and putative p53 site is associated with altered allele-specific expression of ERCC5 (XPG) transcript in normal human bronchial epithelium.

Thomas M Blomquist1, Erin L Crawford, James C Willey.   

Abstract

ERCC5 (XPG) is a key component of the nucleotide excision DNA repair pathway. In two recent case-control studies, we determined that ERCC5 transcript expression pattern in grossly normal human bronchial epithelial cells (NBEC) was different in individuals diagnosed with lung cancer compared with non-lung cancer controls. In this study, we tested the hypothesis that variation at cis-acting sites contributed to observed variation in ERCC5 transcript expression in NBEC. Allele-specific expression (ASE) was measured at transcribed polymorphic site rs1047768 in exon 2 of ERCC5 in NBEC complementary DNA (cDNA) of 22 individuals using allele-specific competitive polymerase chain reaction. ASE at rs1047768 was then assessed for association with allelotype at polymorphic sites rs751402 (E2F1 and YY1 recognition and response site) and rs2296147 (putative P53 recognition site) in the proximal promoter and 5' untranslated region, respectively, of ERCC5. Interindividual variation in recombination between rs751402, rs2296147 and rs1047768 in poly-heterozygotes was controlled for by allele-specific sequencing. Measured rs1047768 T:C allelic ratio was (i) significantly higher in NBEC cDNA compared with genomic DNA controls (P < 0.001) among samples heterozygous at both rs751402 and rs2296147; (ii) less high (P = 0.02) for samples homozygous at rs751402 but heterozygous at rs2296147 and (iii) not significantly different (P = 0.18) for doubly homozygous individuals. Here, we demonstrate that rs751402 A allele and rs2296147 T allele are associated with higher ASE of ERCC5 T allele transcript at rs1047768 in NBEC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233728      PMCID: PMC2893795          DOI: 10.1093/carcin/bgq057

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  46 in total

1.  Translational reprogramming following UVB irradiation is mediated by DNA-PKcs and allows selective recruitment to the polysomes of mRNAs encoding DNA repair enzymes.

Authors:  Ian R Powley; Alexander Kondrashov; Lucy A Young; Helen C Dobbyn; Kirsti Hill; Ian G Cannell; Mark Stoneley; Yi-Wen Kong; Julia A Cotes; Graeme C M Smith; Ron Wek; Christopher Hayes; Timothy W Gant; Keith A Spriggs; Martin Bushell; Anne E Willis
Journal:  Genes Dev       Date:  2009-05-15       Impact factor: 11.361

2.  TAF12 recruits Gadd45a and the nucleotide excision repair complex to the promoter of rRNA genes leading to active DNA demethylation.

Authors:  Kerstin-Maike Schmitz; Nina Schmitt; Urs Hoffmann-Rohrer; Andrea Schäfer; Ingrid Grummt; Christine Mayer
Journal:  Mol Cell       Date:  2009-02-13       Impact factor: 17.970

3.  Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.

Authors:  Mariano Monzo; Isabel Moreno; Alfons Navarro; Rafael Ibeas; Rosa Artells; Bernat Gel; Francisco Martinez; Jose Moreno; Raquel Hernandez; Marta Navarro-Vigo
Journal:  Oncology       Date:  2008-01-17       Impact factor: 2.935

4.  Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk.

Authors:  Xiaowei Chen; Joellen Weaver; Betsy A Bove; Lisa A Vanderveer; Susan C Weil; Alexander Miron; Mary B Daly; Andrew K Godwin
Journal:  Hum Mol Genet       Date:  2008-01-19       Impact factor: 6.150

5.  XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.

Authors:  Roberta Bartolucci; Jia Wei; Jose Javier Sanchez; Laia Perez-Roca; Imane Chaib; Francesco Puma; Raffaele Farabi; Pedro Mendez; Fausto Roila; Tatsuro Okamoto; Miquel Taron; Rafael Rosell
Journal:  Clin Lung Cancer       Date:  2009-01       Impact factor: 4.785

6.  Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer.

Authors:  Laura Valle; Tarsicio Serena-Acedo; Sandya Liyanarachchi; Heather Hampel; Ilene Comeras; Zhongyuan Li; Qinghua Zeng; Hong-Tao Zhang; Michael J Pennison; Maureen Sadim; Boris Pasche; Stephan M Tanner; Albert de la Chapelle
Journal:  Science       Date:  2008-08-14       Impact factor: 47.728

7.  NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans.

Authors:  S Hooker; C Bonilla; F Akereyeni; C Ahaghotu; R A Kittles
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-11-20       Impact factor: 5.554

8.  The role of Bcl-x(L) protein in nucleotide excision repair-facilitated cell protection against cisplatin-induced apoptosis.

Authors:  Stephanie L Lomonaco; Xiaoxin S Xu; Gan Wang
Journal:  DNA Cell Biol       Date:  2009-06       Impact factor: 3.311

9.  Validating discovered Cis-acting regulatory genetic variants: application of an allele specific expression approach to HapMap populations.

Authors:  Susana Campino; Julian Forton; Srilakshmi Raj; Bert Mohr; Sarah Auburn; Andrew Fry; Valentina D Mangano; Claire Vandiedonck; Anna Richardson; Kirk Rockett; Taane G Clark; Dominic P Kwiatkowski
Journal:  PLoS One       Date:  2008-12-31       Impact factor: 3.240

10.  Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.

Authors:  Kishore Guda; Leanna Natale; James Lutterbaugh; Georgia L Wiesner; Susan Lewis; Stephan M Tanner; Jerneja Tomsic; Laura Valle; Albert de la Chapelle; Robert C Elston; Joseph Willis; Sanford D Markowitz
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

View more
  13 in total

Review 1.  Research progress in allele-specific expression and its regulatory mechanisms.

Authors:  Uma Gaur; Kui Li; Shuqi Mei; Guisheng Liu
Journal:  J Appl Genet       Date:  2013-04-23       Impact factor: 3.240

2.  Genetic association between ERCC5 rs17655 polymorphism and lung cancer risk: evidence based on a meta-analysis.

Authors:  Yujia Liang; Jun Deng; Ying Xiong; Songping Wang; Wei Xiong
Journal:  Tumour Biol       Date:  2014-03-05

3.  Haplotype and diplotype analyses of variation in ERCC5 transcription cis-regulation in normal bronchial epithelial cells.

Authors:  Xiaolu Zhang; Erin L Crawford; Thomas M Blomquist; Sadik A Khuder; Jiyoun Yeo; Albert M Levin; James C Willey
Journal:  Physiol Genomics       Date:  2016-05-27       Impact factor: 3.107

4.  Role of ERCC5 polymorphism in risk of hepatocellular carcinoma.

Authors:  Angela J Yoon; Wu-Hsien Kuo; Chiao-Wen Lin; Shun-Fa Yang
Journal:  Oncol Lett       Date:  2011-06-10       Impact factor: 2.967

5.  CEBPG Exhibits Allele-Specific Expression in Human Bronchial Epithelial Cells.

Authors:  Thomas M Blomquist; Ronald D Brown; Erin L Crawford; Ivana de la Serna; Kandace Williams; Youngsook Yoon; Dawn-Alita Hernandez; James C Willey
Journal:  Gene Regul Syst Bio       Date:  2013-07-04

6.  XPG gene polymorphisms and cancer susceptibility: evidence from 47 studies.

Authors:  Jiawen Huang; Xiaoqi Liu; Ling-Ling Tang; Jian-Ting Long; Jinhong Zhu; Rui-Xi Hua; Jufeng Li
Journal:  Oncotarget       Date:  2017-06-06

7.  A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells.

Authors:  Jiyoun Yeo; Erin L Crawford; Xiaolu Zhang; Sadik Khuder; Tian Chen; Albert Levin; Thomas M Blomquist; James C Willey
Journal:  BMC Cancer       Date:  2017-05-02       Impact factor: 4.430

8.  Polymorphisms in the ERCC5 gene and risk of esophageal squamous cell carcinoma (ESCC) in Eastern Chinese populations.

Authors:  Mei-Ling Zhu; Ting-Yan Shi; Hai-Chuan Hu; Jing He; Mengyun Wang; Li Jin; Ya-Jun Yang; Jiu-Cun Wang; Meng-Hong Sun; Huan Chen; Kuai-Le Zhao; Zhen Zhang; Hai-Quan Chen; Jia-Qing Xiang; Qing-Yi Wei
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

9.  XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.

Authors:  Fang Wang; Shao-Dan Zhang; Hong-Mei Xu; Jin-Hong Zhu; Rui-Xi Hua; Wen-Qiong Xue; Xi-Zhao Li; Tong-Min Wang; Jing He; Wei-Hua Jia
Journal:  Oncotarget       Date:  2016-03-08

10.  Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository.

Authors:  E L Crawford; A Levin; F Safi; M Lu; A Baugh; X Zhang; J Yeo; S A Khuder; A M Boulos; P Nana-Sinkam; P P Massion; D A Arenberg; D Midthun; P J Mazzone; S D Nathan; R Wainz; G Silvestri; J Tita; J C Willey
Journal:  BMC Pulm Med       Date:  2016-01-22       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.